All In Biotech

Drug Trial Radar · NCT06905288

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Apr 2, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.

Conditions

  • Ankylosing Spondylitis

Interventions

  • SecukinumabDrug

    This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)Time frame: Baseline and 28 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Busan, South Korea · Recruiting

  • Novartis Investigative Site

    Gwangju, South Korea · Recruiting

  • Novartis Investigative Site

    Jinju, Gyeongsangnam-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.